Results 181 to 190 of about 8,174 (197)

The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19

Journal of Antimicrobial Chemotherapy, 2020
Saeid Bitaraf, Anahita Sadeghi, Shokrollah Salmanzadeh   +2 more
exaly  

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence

Hepatology, 2016
Eugene R Schiff, John M Vierling, Charles S Landis   +2 more
exaly  

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

New England Journal of Medicine, 2015
Mark S Sulkowski, Douglas T Dieterich
exaly  

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

Gut, 2015
Gideon Hirschfield, Stephen D Shafran, Paul J Thuluvath   +2 more
exaly  

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

Hepatology, 2016
Peter Angus, Gregory J Dore, Stanislas Pol   +2 more
exaly  

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

Hepatology, 2012
Yoshiyasu Karino
exaly  

A UHPLC–MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma

Journal of Pharmaceutical and Biomedical Analysis, 2016
Amedeo De Nicolò, Lucio Boglione, Chiara Simona Cardellino   +2 more
exaly  

Daclatasvir/simeprevir

Reactions Weekly, 2016
openaire   +1 more source

Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation

Clinical Gastroenterology and Hepatology, 2015
Jérôme Dumortier, Claire Fougerou-Leurent, Francois Durand   +2 more
exaly  

Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real‐world results from 18 378 patients in Egypt

Alimentary Pharmacology and Therapeutics, 2018
Heba Omar, Mohamed El Kassas, I Waked
exaly